Dermocosmetics was L’Oreal’s biggest growth story in 2020, benefiting from shifting consumer priorities during the COVID crisis and reinvigorated faith in the recommendations of healthcare professionals. Makeup sales tanked, but that could well reverse with the advent of another Roaring Twenties post-pandemic, L’Oreal leadership suggests.
Already on a downswing pre-COVID, makeup was a drag on L’Oreal SA’s fiscal 2020 performance, slamming its Consumer Products and North American businesses especially hard.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
Beiersdorf AG hit some initial bumps with a repositioning of its business in China, but the firm is optimistic about the rollout of Thiamidol Skin Care In 2026.
L’Oréal Groupe reports in a first quarter presentation that its US business was more challenging than anticipated, while China “was slightly less bad” and Europe represented the best growth contributor. Separately, LVMH's Sephora sees ‘less momentum’ in its US business as competitor Amazon takes an aggressive position on beauty pricing.
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
Coty Inc. reports fiscal second quarter sales slipped 3% on a reported basis to $1.67bn, reflecting further slowing of the mass beauty market, particularly color cosmetics.
France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.
The expansion of Ulta Beauty in Target stores are paused for now as Ulta Beauty Inc. and Target Corp. “lean into” the 610 stores already established and consider how to drive efficiencies and leverage learnings, says new President and CEO Kecia Steelman.
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
